Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59:263-268.

Virtanen R, Savola JM, Saano V. Characterization of selectivity, specificity and potency of medetomidine as an alpha2-adrenoceptor agonist. Eur J Pharmacol. 1988;150:9-14.

Hall JE, Uhrich TD, Barney JA. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90:699-705.

Curtis FG, Castiglia YMM, Stolf AA. Dexmedetomidina e sufentanil como analgésicos per-operatórios: Estudo comparativo. Rev Bras Anestesiol. 2002;52:525-534.

Marangoni MA, Castiglia YMM, Medeiros TP. Eficácia analgésica da dexmedetomidina comparada ao sufentanil em cirurgias intraperitoneais: Estudo comparativo. Rev Bras Anestesiol. 2005:19-27.

Bloor BC, Ward DS, Belleville JP. Effects of intravenous dexmedetomidine in humans. II: Hemodynamic changes. Anesthesiology. 1992;77:1134-1142.

Dyck JB, Maze M, Haack C. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrocholoride in adult human volunteers. Anesthesiology. 1993;78:813-820.

Karol MD, Maze M. Pharmacokinetics and interaction of dexmedetomidine in humans. Ballière Clin Anesthesiol. 2000;14:261-269.

Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology. 2000;93:1345-1349.

Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes. Pharmacol Res. 2001;44:195-208.

Scheinin M. Pihlavisis M Molecular pharmacology of alpha2-adrenoceptor agonists. 2000:247-260.

Hodgson PS, Liu SS. New developments in spinal anesthesia. Anesthesiol Clin North Am. 2000;18:235-249.

McCallum JB, Boban N, Hogan Q. The mechanism of alpha2-adrenergic inhibition of sympathetic ganglionic transmission. Anesth Analg. 1998;87:503-510.

Khan ZP, Ferguson CN, Jones RM. Alpha2 and imidazoline receptor agonists: Their pharmacology and therapeutic role. Anaesthesia. 1999;54:146-165.

Talke P, Chen R, Thomas B. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg. 2000;90:834-839.

Ebert TJ, Hall JE, Barney JA. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382-394.

Jalonen J, Hynynen M, Kuitunen A. Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Anesthesiology. 1997;86:331-345.

Talke P, Lobo E, Brown R. Systemically administered alpha2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology. 2003;99:65-70.

Villela NR, Nascimento Jr P, Carvalho LR. Efeitos cardiovasculares de duas doses de dexmedetomidina. Estudo experimental em cães. Rev Bras Anestesiol. 2003;53:784-796.

Bekker A, Gold M, Basile J. Hemodynamic and respiratory changes related to the use of dexmedetomidine in patients undergoing awake carotid endarterectomy. Anesthesiology. 2003;100:A136.

Lawrence CJ, Prinzen FW, de Lange S. The effect of dexmedetomidine on the balance of myocardial energy requirement an oxygen supply and demand. Anesth Analg. 1996;82:544-550.

Wijeysundera DN, Naik JS, Beattie WS. Alpha2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med. 2003;114:742-752.

Groeben H, Mitzner W, Brown RH. Effects of the alpha2-adrenoceptor agonist dexmedetomidine on bronchoconstriction in dogs. Anesthesiology. 2004;100:359-363.

Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care Med. 2000;4:302-308.

Venn RM, Bryant A, Hall GM. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine, and inflammatory responses in postoperative patients needing sedation in the intensive care unit. Br J Anaesth. 2001;86:650-656.

Xu H, Aibiki M, Seki K. Effects of dexmedetomidine, an alpha2-adrenoceptor agonist, on renal sympathetic nerve activity, blood pressure, heart rate and central venous pressure in urethane-anesthetized rabbits. J Auton Nerv Syst. 1998;71:48-54.

Villela NR, Nascimento Jr P, Carvalho LR. Efeitos da dexmedetomidina sobre o sistema renal e sobre a concentração plasmática do hormônio antidiurético: Estudo experimental em cães. Rev Bras Anestesiol. 2005;55:429-440.

Pettinger WA, Umemura S, Smyth DD. Renal alpha2-adrenoceptors and the adenylate cyclase-cAMP system: biochemical and physiological interactions. Am J Physiol. 1987;252:F199-208.

Malmberg AB, Hedley LR, Jasper JR. Contribution of alpha2 receptor subtypes to nerve injury-induced pain and its regulation by dexmedetomidine. Br J Pharmacol. 2001;132:1827-1836.

Stone LS, MacMillan LB, Kitto KF. The alpha2A adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci. 1997;17:7157-7165.

Unlugenc H, Gunduz M, Guler T. The effect of pre-anaesthetic administration of intravenous dexmedetomidine on postoperative pain in patients receiving patient-controlled morphine. Eur J Anaesthesiol. 2005;22:386-391.

Martin E, Ramsay G, Mantz J. The role of alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intens Care Med. 2003;18:29-41.

Venn RM, Grounds RN. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth. 2001;87:684-690.

Karlsson BR, Forsman M, Roald OK. Effect of dexmedetomidine, a selective and potent alpha2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs. Anesth Analg. 1990;71:125-129.

Zornow MH, Fleischer JE, Scheller MS. Dexmedetomidine, an alpha2-adrenergic agonist, decreases cerebral blood flow in the isoflurane-aneshetized dog. Anesth Analg. 1990;70:624-630.

McPherson RW, Koehler RC, Traystman RJ. Hypoxia, alpha2-adrenergic, and nitric oxide-dependent interactions on canine cerebral blood flow. Am J Physiol. 1994;266:H482.

Lam AM, Bhatia S, Lee LA. Influence of dexmedetomidine on CO2 reactivity and cerebral autoregulation in healthy volunteers. Anesthesiology. 2001;95:A341.

Ohata H, Iida H, Dohi S. Intravenous dexmedetomidine inhibits cerebrovascular dilatation induced by isoflurane and sevoflurane in dogs. Anesth Analg. 1999;89:370-377.

Ulrich K, Kuschinsky W. In vivo effects of alpha-adrenoreceptor agonists and antagonists on pial veins of cats. Stroke. 1985;16:880-884.

Zornow MH, Scheller MS, Sheehan PB. Intracranial pressure effects of dexmedetomidine in rabbits. Anesth Analg. 1992;75:232-237.

Talke P, Tong C, Lee HW. Effect of dexmedetomidine on lumbar cerebrospinal fluid pressure in humans. Anesth Analg. 1997;85:358-364.

Hall JE, Uhrich TD, Barney JA. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90:699-705.

Jolkkonen J, Puurunen K, Koistinaho J. Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol. 1999;372:31-36.

Paris A, Tonner PH. Dexmedetomidine in anaesthesia. Curr Opin Anaesthesiol. 2005;18:412-418.

Kuhmonen J, Pokorny J, Miettinen R. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology. 1997;87:371-377.

Engelhard K, Werner C, Eberspacher E. The effect of the alpha2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S (+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003;96:524-531.

Chen Y, Zhao Z, Code WE. A correlation between dexmedetomidine-induced biphasic increases in free cytosolic calcium concentration and energy metabolism in astrocytes. Anesth Analg. 2000;91:353-357.

Talke P, Bickler PE. Effects of dexmedetomidine on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices. Anesthesiology. ;85:1996.

Laudenbach V, Mantz J, Langercrantz H. Effects of alpha2-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. Anesthesiology. 2002;96:134-141.

Bekker A, Sturaitis MK. Dexmedetomidine for neurological surgery. Neurosurgery. 2005;57:1-10.

Mack PF, Perrine K, Kobylarz E. Dexmedetomidine and neurocognitive testing in awake craniotomy. J Neurosurg Anesthesiol. 2004;16:20-25.

See JJ, Manninen PH. Anesthesia for neuroradiology. Curr Opin Anaesthesiol. 2005;18:437-441.

Everett LL, Van Rooyen IF, Warner MH. Use of dexmedetomidine in awake craniotomy in adolescents: report of two cases. Paediatr Anaesth. 2006;16:338-342.

Venkatraghavan L, Manninen P, Mak P. Anesthesia for functional neurosurgery. Review of complications. J Neurosurg Anesthesiol. 2006;18:64-67.

Bekker AY, Basile J, Gold M. Dexmedetomidine for awake carotid endarterectomy: efficacy, hemodynamic profile, and side effects. J Neurosurg Anesthesiol. 2004;16:126-135.

Lee CZ, Young WL. Anesthetic considerations for interventional neuroradiology. ASA Refresher Courses in Anesthesiol. 2005;33:145-154.

Pasternak JJ, Lanier WL. Neuroanesthesiology review. J Neurosurg Anesthesiol. 2005;17:2-8.

Sturatis M, Kroin J, Swamidoss CS. Effect of intraoperative dexmedetomidine infusion on hemodynamic stability during brain tumor resection. Anesthesiology. 2002;97:A310.